M&A Deal Summary

Biohaven Pharmaceutical Holding Acquires Channel Biosciences

On February 25, 2022, Biohaven Pharmaceutical Holding acquired life science company Channel Biosciences from Knopp Biosciences for 100M USD

Acquisition Highlights
  • This is Biohaven Pharmaceutical Holding’s 1st transaction in the Life Science sector.
  • This is Biohaven Pharmaceutical Holding’s largest (disclosed) transaction.
  • This is Biohaven Pharmaceutical Holding’s 1st transaction in the United States.
  • This is Biohaven Pharmaceutical Holding’s 1st transaction in Pennsylvania.

M&A Deal Summary
Date 2022-02-25
Target Channel Biosciences
Sector Life Science
Buyer(s) Biohaven Pharmaceutical Holding
Sellers(s) Knopp Biosciences
Deal Type Divestiture
Deal Value 100M USD

Target

Channel Biosciences

Pittsburgh, Pennsylvania, United States
Channel Biosciences is a developer of the Kv7 platform and BHV-7000 is a potent activator of Kv7.2/Kv7.3, key subunits involved in neuronal signaling and in regulating the hyperexcitable state in epilepsy.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Biohaven Pharmaceutical Holding

New Haven, Connecticut, United States
Category Company
Founded 2013
Sector Life Science
Employees928
Revenue 463M USD (2021)
DESCRIPTION

Biohaven Pharmaceutical Holding is a biopharmaceutical company engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. Biohaven Pharmaceutical Holding was incorporated in 2013 and is based in New Haven, Connecticut.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
State (Pennsylvania) 1 of 1
Country (United States) 1 of 1
Year (2022) 1 of 1
Size (of disclosed) 1 of 1

Seller(S) 1

SELLER

Knopp Biosciences

Pittsburgh, Pennsylvania, United States
Category Company
Sector Life Science
DESCRIPTION

Knopp Biosciences is a drug discovery and development company focused on delivering breakthrough treatments for immunological and neurological diseases with high unmet needs. Knopp's clinical-stage oral small molecule, dexpramipexole, is in development for eosinophilic asthma. Knopp Biosciences is based in Pittsburgh, Pennsylvania.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
State (Pennsylvania) 1 of 1
Country (United States) 1 of 1
Year (2022) 1 of 1
Size (of disclosed) 1 of 1
Mergr

Product

Company

Legal